問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Neurology

Division of Pediatrics

China Medical University Hospital-Taipei (在職)

Division of Neurology

更新時間：2023-09-19

周宜卿Chou, I-Ching
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • iching@mail.cmuh.org.tw

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

周宜卿

List

12Cases

2021-03-17 - 2035-12-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-03-17 - 2035-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2011-11-01 - 2012-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2010-10-01 - 2011-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2022-07-22 - 2022-11-09

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2014-07-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2015-07-01 - 2020-12-31

Phase III

A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of lacosamide as adjunctive therapy in subjects with epilepsy ≥1 month to <4 years of age with partial-onset seizures

  • Condition/Disease

    partial-onset seizures

  • Test Drug

    VIMPAT® Lacosamide

Participate Sites
3Sites

Terminated2Sites

2015-04-01 - 2018-12-31

Phase III

a double-blind, randomized, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy

  • Condition/Disease

    idiopathic generalized epilepsy

  • Test Drug

    VIMPAT® Lacosamide

Participate Sites
3Sites

Terminated2Sites

周宜卿
China Medical University Hospital-Taipei

未分科

2013-12-01 - 2018-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2015-05-01 - 2022-07-31

Phase III

A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy compared with Levetiracetam as Monotherapy in Pediatric Subjects With New or Recent - Onset Epilepsy.

  • Condition/Disease

    Epilepsy

  • Test Drug

    Topamax F.C. Tablets 25mg, 50mg, 100mg and Topamax Sprinkle Capsule 25mg

Participate Sites
6Sites

Terminated5Sites

周宜卿
China Medical University Hospital-Taipei

未分科

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB